Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Autologous BM-MNC and Liberation Therapy in RRMS
NCT02587806Phase 2Unknown
- Sponsor
- Novo Cellular Medicine Institute
- Start
- Feb 2015
- Primary completion
- Feb 2017
- Modality
- Stem Cell Therapies
- Countries
- 2
01
Overview
A Phase 2 trial of autologous bone marrow-derived mononuclear cell in multiple sclerosis (MS), sponsored by Novo Cellular Medicine Institute. Status: unknown.
02
Drugs
autologous bone marrow-derived mononuclear cell
03
Conditions
multiple sclerosis (MS)
Beyond the preview
Go deeper on NCT02587806.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02587806.